Benefit of nectin-4 targeting with enfortumab vedotin confirmed
Nat Rev Urol
.
2021 Apr;18(4):190.
doi: 10.1038/s41585-021-00449-1.
Author
Diana Romero
1
Affiliation
1
Chief Editor, Nature Reviews Clinical Oncology, . nruro@nature.com.
PMID:
33692500
DOI:
10.1038/s41585-021-00449-1
No abstract available
Publication types
Comment
MeSH terms
Antibodies, Monoclonal*
Cell Adhesion Molecules / genetics
Humans
Nectins
Urologic Neoplasms*
Substances
Antibodies, Monoclonal
Cell Adhesion Molecules
Nectins
enfortumab vedotin